There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC value of 0.2 µM against , and a selectivity index value of 187, together with in vivo activity on the /hamster model. Attempts to establish structure-activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000572PMC
http://dx.doi.org/10.3390/molecules27072313DOI Listing

Publication Analysis

Top Keywords

potential 2-substituted
4
2-substituted quinolines
4
quinolines antileishmanial
4
antileishmanial drug
4
drug candidates
4
candidates cost-effective
4
cost-effective drugs
4
drugs treat
4
treat leishmaniasis
4
leishmaniasis strategy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!